ArticleBlood advances2019
Progression of mycosis fungoides occurs through divergence of tumor immunophenotype by differential expression of HLA-DR.
Article in Blood advances, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 2 syntheses or guidelines pooled it, 32 citations in OpenAlex.
- Allogeneic stem cell transplant for treatment of mycosis fungoides and Sezary syndrome: a systematic review and meta-analysis.Bone marrow transplantation · 2024Pooled it
- Pooled it
- Article
- Review
- CD70 identifies alloreactive T cells and represents a potential target for prevention and treatment of acute GVHD.Blood advances · 2024Article
- MHC-I upregulation safeguards neoplastic T cells in the skin against NK cell-mediated eradication in mycosis fungoides.Nature communications · 2024Article
- Article
- HLA-DR Helps to Differentiate Erythrodermic Cutaneous T-cell Lymphoma from Erythrodermic Inflammatory Dermatoses in Flow Cytometry.Acta dermato-venereologica · 2023Article
- TIGIT is a key inhibitory checkpoint receptor in lymphoma.Journal for immunotherapy of cancer · 2023Article
- Blocking STAT3/5 through direct or upstream kinase targeting in leukemic cutaneous T-cell lymphoma.EMBO molecular medicine · 2022Article
- Article
- PD-1 improves accurate detection of Sezary cells by flow cytometry in peripheral blood in mycosis fungoides/Sezary syndrome.Cytometry. Part B, Clinical cytometry · 2022Article
- Cognition/Psychological Burden and Resilience in Cutaneous T-Cell Lymphoma and Psoriasis Patients: Real-Life Data and Implications for the Treatment.BioMed research international · 2022Article
- Review
- Article
- Determining the immune environment of cutaneous T-cell lymphoma lesions through the assessment of lesional blood drops.Scientific reports · 2021Article
- Sézary syndrome and mycosis fungoides: An overview, including the role of immunophenotyping.Cytometry. Part B, Clinical cytometry · 2021Review
- Immune Check Point Inhibitors in Primary Cutaneous T-Cell Lymphomas: Biologic Rationale, Clinical Results and Future Perspectives.Frontiers in oncology · 2021Review
- Protein and mRNA Expression Levels of Interleukin-17A, -17F and -22 in Blood and Skin Samples of Patients with Mycosis Fungoides.Acta dermato-venereologica · 2020Article
- Enhancing antitumor immunity through checkpoint blockade as a therapeutic strategy in T-cell lymphomas.Blood advances · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 1 institution in 1 country.
Funding
Abstract
Immunotherapy is a valuable treatment for many cancer patients, and there is considerable interest in understanding the mechanisms of immune evasion to guide appropriate management. Mycosis fungoides (MF) is a malignant disorder of skin-homing CD4
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.